Shell Asset Management CO Bluebird Bio, Inc. Transaction History

Shell Asset Management CO

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 09, 2022	SELL	$2.94 - $5.23 $50,482 - $89,804	-17,171 Closed	0 $0
Q1 2022 May 04, 2022	SELL	$4.07 - $10.6 $10,280 - $26,775	-2,526 Reduced 12.82%	17,171 $83,000
Q4 2021 Feb 09, 2022	BUY	$8.96 - $16.31 $1,478 - $2,691	165 Added 0.84%	19,697 $197,000
Q3 2021 Nov 04, 2021	SELL	$11.24 - $21.0 $9,441 - $17,640	-840 Reduced 4.12%	19,532 $373,000
Q2 2021 Aug 12, 2021	BUY	$18.04 - $22.09 $19,844 - $24,299	1,100 Added 5.71%	20,372 $651,000
Q1 2021 May 10, 2021	BUY	$16.59 - $33.89 $132,620 - $270,916	7,994 Added 70.88%	19,272 $581,000
Q4 2020 Feb 16, 2021	BUY	$27.5 - $37.92 $169,812 - $234,156	6,175 Added 121.01%	11,278 $488,000
Q2 2020 Aug 10, 2020	SELL	$27.12 - $45.97 $2,169 - $3,677	-80 Reduced 1.54%	5,103 $311,000
Q1 2020 May 11, 2020	SELL	$26.16 - $63.5 $2,066 - $5,016	-79 Reduced 1.5%	5,183 $238,000
Q4 2019 Feb 13, 2020	SELL	$46.96 - $61.67 $6,433 - $8,448	-137 Reduced 2.54%	5,262 $462,000
Q3 2019 Nov 12, 2019	SELL	$59.47 - $93.1 $2,735 - $4,282	-46 Reduced 0.84%	5,399 $496,000
Q2 2019 Aug 12, 2019	SELL	$75.84 - $105.21 $9,404 - $13,046	-124 Reduced 2.23%	5,445 $693,000
Q1 2019 May 09, 2019	BUY	$64.44 - $104.11 $38,212 - $61,737	593 Added 11.92%	5,569 $876,000
Q4 2018 Feb 13, 2019	SELL	$59.1 - $93.26 $23,640 - $37,304	-400 Reduced 7.44%	4,976 $494,000
Q2 2018 Aug 10, 2018	SELL	$99.64 - $127.59 $28,696 - $36,745	-288 Reduced 5.08%	5,376 $844,000
Q4 2017 Feb 09, 2018	BUY	$81.25 - $130.7 $460,200 - $740,284	5,664	5,664 $1.01 Million

152

63.7M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $24.7M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Shell Asset Management CO, based on Form 13F filings with the SEC.

Stay updated on Shell Asset Management CO with notifications on news.